InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
stocktrademan Free
06/20/15 12:06 PM

Biotie Therapies Corp. (BIOZF) RSS Feed

Posts (Today)
Posts (Total)
Biotie Therapies Corp. Joukahaisenkatu 6 Turku, 20520 Finland Phone: 358 2274 8900 Fax: 358 2274 8910 Website: Biotie Therapies Corp., a drug development company, focuses on the development of drugs for neurodegenerative and psychiatric disorders primarily in Finland and the United States. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson's disease that is in Phase III development; and Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which has completed in Phase II trial. The company's products also comprise BTT1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 in Phase II development in fibrotic conditions and received orphan drug designation for the treatment of primary sclerosing cholangitis; and SYN120, an oral, potent, dual antagonist of the 5-HT6 and 5-HT2A receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose for subsequent Phase II studies. Biotie Therapies Corp. is based in Turku, Finland.
BIOZF Latest News
  • No Recent News Available for this company!
New Post